Baidu
map

Biomaterials:药物所甘勇组双阳离子型核壳脂质体纳米粒(DLCS-NP)研究取得进展

2013-05-06 中科院药物所 中科院药物所

眼部疾病的常用治疗方式是局部给以药物溶液(例如滴眼液),这些传统剂型占据市售制剂的90%左右。然而,眼部的生理屏障以及候选药物的低溶解性为眼部给药系统的发展带来许多难题。 最近,各种旨在提高难溶性药物生物利用度的眼部给药方式大量出现。上海药物所甘勇课题组专题综述了这些眼部给药方式,包括水凝胶、聚合物胶束、纳米混悬液和脂质纳米载体等。同时,深入阐述了脂质纳米载体,包括乳液、脂质体、立方液晶、囊泡等

眼部疾病的常用治疗方式是局部给以药物溶液(例如滴眼液),这些传统剂型占据市售制剂的90%左右。然而,眼部的生理屏障以及候选药物的低溶解性为眼部给药系统的发展带来许多难题。

最近,各种旨在提高难溶性药物生物利用度的眼部给药方式大量出现。上海药物所甘勇课题组专题综述了这些眼部给药方式,包括水凝胶、聚合物胶束、纳米混悬液和脂质纳米载体等。同时,深入阐述了脂质纳米载体,包括乳液、脂质体、立方液晶、囊泡等,为眼部药物传递提供许多优势,比如提高难溶性药物的生物利用度、靶向给药、控制药物释放以及降低全身副作用等。(相关工作主要由甘莉、王静完成:Drug Discovery Today, in press.)

依据脂质体纳米粒作为眼用载体的独特优势,甘勇课题组设计研究了一种新型双阳离子型核壳脂质体纳米粒(DLCS-NP)。采用薄膜分散水化-挤膜法,直接将旋干的脂质膜与分散的壳聚糖纳米粒(CS-NP)混悬液水化,自组装形成核壳结构的阴离子脂质体纳米粒(LCS-NP),随后利用阳离子N-[1-(2,3-二油酰基) ]-N,N,N-三甲酰丙烷甲基硫酸盐与磷脂双分子层的亲和作用,在LCS-NP表面形成正电荷磷脂修饰层,形成DLCS-NP。该具有独特双阳离子型核壳脂质体纳米粒,能够显著延长载体角膜滞留时间,提高细胞摄取量,并具有一定的溶酶体逃逸能力,取得了理想的体内外眼表基因转染效果,为眼表疾病的基因治疗开辟了新途径。(相关工作主要由蒋敏、甘莉完成:Biomaterials, 2012, 33: 7621-7630.)

该项研究取得了上海市自然科学基金 (No.11ZR1444700)、国家自然科学基金资助项目(No.81102387)、国家科技重大专项“重大新药创制” (No.2009ZX09301-01) 和国家重点基础研究发展计划 (No.2009CB930300)的资助。

纳米粒相关的拓展阅读: 

Cationic core-shell liponanoparticles for ocular gene delivery.
Abstract
To achieve enhanced gene transfection efficiency with ocular eye-drop therapy, a cationic core-shell liponanoparticle (DLCS-NP) was designed by enveloping the plasmid-laden chitosan nanoparticle (CS-NP) into a cationic lipid shell. The cellular uptake of DLCS-NP was up to 1.25-fold and 5-fold higher than that of CS-NP and lipid-coated chitosan nanoparticles (LCS-NP), respectively. Further endocytosis inhibition investigation discovered that facilitated by the cationic outer lipid layer, several other distinct pathways (besides clathrin-mediated endocytosis) were involved in the endocytosis of DLCS-NP. Endolysosome trafficking experiment verified that cationic lipid coating could facilitate the endolysosome escape of DLCS-NP. Consequently, using enhanced green fluorescence protein (EGFP) as a reporter gene, DLCS-NP-treated human conjunctival epithelial cells exhibited 3.1- and 3.5-fold more intense EGFP expression than that of LCS-NP and CS-NP, respectively. Finally, in vivo transfection experiments on rabbits revealed that EGFP expression exhibited 2.52-fold increase in DLCS-NP group than that of CS-NP group. In summary, this type of cationic core-shell liponanoparticle, possessing multiple functions including better DNA protecting effect, superior cellular uptake efficiency, utilization of multiple endocytic pathways, and endolysosome escaping ability, may represent a promising strategy for ocular gene delivery.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
    2013-12-07 klivis
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
    2013-10-30 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2049963, encodeId=48d02049963d8, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Jul 01 07:56:00 CST 2013, time=2013-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976437, encodeId=7a2719e6437d3, content=<a href='/topic/show?id=06fd84425c8' target=_blank style='color:#2F92EE;'>#脂质体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84425, encryptionId=06fd84425c8, topicName=脂质体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Feb 09 22:56:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007597, encodeId=3ca4200e59737, content=<a href='/topic/show?id=853610e4959' target=_blank style='color:#2F92EE;'>#LCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10749, encryptionId=853610e4959, topicName=LCS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Dec 07 14:56:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916952, encodeId=a7d41916952cf, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 30 04:56:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772917, encodeId=eba81e729173e, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Dec 02 21:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784621, encodeId=1e981e84621ed, content=<a href='/topic/show?id=cc876031c8' target=_blank style='color:#2F92EE;'>#DLCS-NP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6031, encryptionId=cc876031c8, topicName=DLCS-NP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Jun 03 11:56:00 CST 2013, time=2013-06-03, status=1, ipAttribution=)]
    2013-06-03 vera_1203

相关资讯

Sci Signal:抗癌药物或可用于治疗肌肉变性疾病

2012年10月17日目前治疗肌肉损伤的药物很少,肌萎缩和家族性遗传病可以引发肌肉变性,比如迪谢纳肌营养不良症。近日,一项研究发现或许帮助医生们治疗这种肌肉疾病,相关研究由渥太华大学医学院等处的研究者进行,研究成果刊登于10月16日的国际杂志Science Signaling上。 研究者Korneluk教授表示,我们都知道,目前很多制药公司都在积极推进抗癌药物的研发和临床试验,这些抗癌药物都以I

J Pediatrics:研究者呼吁增加新生儿用药相关的药物临床试验

2012年10月27日--临床药物试验是制药企业新药通过FDA的重要步骤,近日,刊登在国际杂志The Journal of Pediatrics上的一篇研究报告评估了儿童及初生婴儿的用药相关临床试验的缺少、以及制药商和研究者如何共同努力开发新的试验方法来使得儿童、初生婴儿的用药更加有效、安全。 来自辛辛那提儿童医院医疗中心以及辛辛那提大学的研究者认为,初生婴儿临床用药试验的缺少是由许多因素引起的

J Thorac Oncol:利用化疗和药物治疗延长对肺癌恶化的控制

2012年12月02日--癌症的主要技能就是它能够发生突变。一旦它沿着这种途径开始开展下去,癌细胞就很容易一次又一次发生突变。这意味着在单个病人体内不同的肿瘤或者甚至相同肿瘤的不同区域可能产生不同的遗传特征。这种异质性有助于癌症逃避来自新的癌症靶向治疗药物的控制。 在这当中,两种靶向药物是克里唑蒂尼(crizotinib)和埃罗替尼(erlotinib)。研究人员想知道这些药物能够被用来治疗哪些

Mol Psychiatr:糖尿病药物或能有效治疗毒品成瘾患者

2012年10月24日Vanderbilt研究人员报告称,目前用于治疗2型糖尿病的药物对治疗毒品成瘾包括可卡因成瘾一样有效。 相关研究结果发表在Molecular Psychiatry杂志上,该研究可以对世界各地的成瘾患者有深远的影响。 内范德比尔特肯尼迪中心和Vanderbilt大学脑科学研究所的研究员Gregg Stanwood博士说,研究已经证明糖尿病治疗过程中涉及到的一个已知的脑机制在

FASEB J:青光眼药物或成为秃顶患者的福音

2012年10月29日 讯 /生物谷BIOON/ --如果你秃顶了,想让自己的头发长出来,那么下面的报道对你绝对有帮助。近日,一项刊登于国际杂志FASEB Journal上的研究报告指出,一种FDA批准的青光眼药物比马前列素,可以促使人们头发再生长,而且该药物已经在增长个体眼睫毛上进行了商业的应用,研究者表示,实际上这种药物还可以促使个体的头发再生。 研究者Valerie Randall表示,我

J Med Chem:开发出新型抗疟疾药物

刊登在国际著名杂志Journal of Medicinal Chemistry上的一篇研究报告中,来自国外的研究者报道说,他们在实验室开发出了一种新型的抑制疟疾发展的药物,其预防抵御疟疾的效果是当前普通疗法的两倍,而且这种新药仅需服用一个剂量即可抵御疟疾感染。 研究者Gary Posner和其同事解释道,每年因为感染疟疾可以导致超过100万人丧生,当前最好的疗法就是所谓的青蒿素联合疗法(ACT)

Baidu
map
Baidu
map
Baidu
map